Lilly Claims 61% of US GLP-1 Market as Novo Bets $23B Pipeline

Lilly holds 61% of the U.S. GLP-1 market and is gaining in pills and Medicare. Novo counters with a $23 billion pipeline bet, but Wall Street wants proof of a turnaround.